WO2000071710A3 - Produits d'expression de genes impliques dans des affections du metabolisme du cholesterol - Google Patents

Produits d'expression de genes impliques dans des affections du metabolisme du cholesterol Download PDF

Info

Publication number
WO2000071710A3
WO2000071710A3 PCT/FR2000/001426 FR0001426W WO0071710A3 WO 2000071710 A3 WO2000071710 A3 WO 2000071710A3 FR 0001426 W FR0001426 W FR 0001426W WO 0071710 A3 WO0071710 A3 WO 0071710A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
genes involved
diseases related
expression products
concerns
Prior art date
Application number
PCT/FR2000/001426
Other languages
English (en)
Other versions
WO2000071710A2 (fr
Inventor
Patrice Denefle
Marie-Francoise Rosier-Montus
Isabelle Arnould-Reguigne
Catherine Prades
Christian Clepet
Original Assignee
Aventis Pharma Sa
Patrice Denefle
Rosier Montus Marie Francoise
Arnould Reguigne Isabelle
Catherine Prades
Christian Clepet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9906587A external-priority patent/FR2794131B1/fr
Priority to IL14583500A priority Critical patent/IL145835A0/xx
Priority to MXPA01011882A priority patent/MXPA01011882A/es
Priority to JP2000620087A priority patent/JP2003518918A/ja
Priority to HU0203164A priority patent/HUP0203164A2/hu
Priority to BR0010916-9A priority patent/BR0010916A/pt
Application filed by Aventis Pharma Sa, Patrice Denefle, Rosier Montus Marie Francoise, Arnould Reguigne Isabelle, Catherine Prades, Christian Clepet filed Critical Aventis Pharma Sa
Priority to AU49318/00A priority patent/AU4931800A/en
Priority to EP00931354A priority patent/EP1183350A2/fr
Priority to KR1020017015017A priority patent/KR20020033627A/ko
Priority to CA002371500A priority patent/CA2371500A1/fr
Publication of WO2000071710A2 publication Critical patent/WO2000071710A2/fr
Publication of WO2000071710A3 publication Critical patent/WO2000071710A3/fr
Priority to NO20015729A priority patent/NO20015729L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des acides nucléiques exprimés à partir de gènes localisés dans le génome humain dans la région 9q31-34 du chromosome 9, susceptibles d'être impliqués dans des maladies génétiquement liées à ce locus chromosomique, notamment les affections du métabolisme des lipoprotéines plasmatiques, plus particulièrement le transport inverse du cholestérol. L'invention concerne également des polypeptides codés par certains de ces acides nucléiques ainsi que des anticorps dirigés spécifiquement contre de tels polypeptides, utiles comme réactifs de diagnostic. L'invention est enfin relative à des vecteurs et des cellules hôtes recombinantes comprenant ces acides nucléiques ou des fragments de ceux-ci.
PCT/FR2000/001426 1999-05-25 2000-05-25 Produits d'expression de genes impliques dans des affections du metabolisme du cholesterol WO2000071710A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002371500A CA2371500A1 (fr) 1999-05-25 2000-05-25 Produits d'expression de genes impliques dans des affections du metabolisme du cholesterol
MXPA01011882A MXPA01011882A (es) 1999-05-25 2000-05-25 Productos de expresion de genes implicados en enfermedades relacionadas con el metabolismo del colesterol.
JP2000620087A JP2003518918A (ja) 1999-05-25 2000-05-25 コレステロール代謝疾患に関与する遺伝子の発現産物
HU0203164A HUP0203164A2 (hu) 1999-05-25 2000-05-25 Koleszterin-metabolizmussal kapcsolatos betegségekben érintett gének expressziós termékei
BR0010916-9A BR0010916A (pt) 1999-05-25 2000-05-25 ácido nucleico, sonda ou iniciador de nucleotìdeo, processos e kits para amplificação de um ácido nucleico, para detecção de presença de um ácido nucléico e de um polipeptìdeo, para seleção de uma molécula ou de uma substância candidata que interage com um polipeptìdeo, vetor recombinante, célula hospedeira recombinante, polipeptìdeo, e, anticorpo
IL14583500A IL145835A0 (en) 1999-05-25 2000-05-25 Expression products of genes involved in diseases related to cholesterol metabolism
AU49318/00A AU4931800A (en) 1999-05-25 2000-05-25 Expression products of genes involved in diseases related to cholesterol metabolism
EP00931354A EP1183350A2 (fr) 1999-05-25 2000-05-25 Produits d'expression de genes impliques dans des affections du metabolisme du cholesterol
KR1020017015017A KR20020033627A (ko) 1999-05-25 2000-05-25 콜레스테롤 대사 관련 질환에 관여된 유전자의 발현산물
NO20015729A NO20015729L (no) 1999-05-25 2001-11-23 Ekspresjonsprodukter av gener involvert i sykdommer relatert til kolesterolmetabolisme

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR99/06587 1999-05-25
FR9906587A FR2794131B1 (fr) 1999-05-25 1999-05-25 Produits d'expression de genes impliques dans des affections associees au metabolisme du cholesterol
US13945099P 1999-06-16 1999-06-16
US60/139,450 1999-06-16

Publications (2)

Publication Number Publication Date
WO2000071710A2 WO2000071710A2 (fr) 2000-11-30
WO2000071710A3 true WO2000071710A3 (fr) 2001-05-17

Family

ID=26234967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/001426 WO2000071710A2 (fr) 1999-05-25 2000-05-25 Produits d'expression de genes impliques dans des affections du metabolisme du cholesterol

Country Status (11)

Country Link
EP (1) EP1183350A2 (fr)
JP (1) JP2003518918A (fr)
KR (1) KR20020033627A (fr)
AU (1) AU4931800A (fr)
BR (1) BR0010916A (fr)
CA (1) CA2371500A1 (fr)
HU (1) HUP0203164A2 (fr)
IL (1) IL145835A0 (fr)
MX (1) MXPA01011882A (fr)
NO (1) NO20015729L (fr)
WO (1) WO2000071710A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367955C (fr) 1999-03-15 2009-05-19 University Of British Columbia Methodes et reactifs permettant de moduler les taux de cholesterol
CA2417900A1 (fr) 2000-08-01 2002-02-07 Amgen Inc. Molecules du type recepteur de complement c3b/c4b et utilisations de ces molecules
AT413701B (de) * 2001-11-06 2006-05-15 Bmt Medizinische Forschung Und Strukturelle und funktionelle charakterisierung von cdw92
EP2123676A4 (fr) * 2007-01-05 2011-01-05 Univ Tokyo Diagnostic et traitement de cancers utilisant un anticorps anti-prg-3
AU2008321840B2 (en) 2007-11-14 2014-02-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-GPR49 antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020165A2 (fr) * 1996-11-06 1998-05-14 Whitehead Institute For Biomedical Research Marqueurs bialleliques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020165A2 (fr) * 1996-11-06 1998-05-14 Whitehead Institute For Biomedical Research Marqueurs bialleliques

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"The WashU-Merck EST Project", Nombre d'accès: R55836; 28-MAi-1995 (Rel. 43, Created) Caractérisation de la séquence: yg89c04.r1 "Homo sapiens cDNA clone 40828 5' similar to contains MER2 repetitive element ";. *
38TH ANNUAL MEETING OF THE COUNCIL ON ARTERIOSCLEROSIS, MIAMI, FLA., USA, NOV. 1984. *
EMBASE numéro d'accès : AC AF088031; Créé le 09-SEPTEMBRE-1998 (Rel. 56) dernière mise à jour le 30-JUIN-1999 (Rel. 60,Version 2) Caractérisation de la séquence : Homo sapiens full length insert cDNA clone ZC22G07.Homo sapiens (human) *
EMBASE, numéro d'accès (AC) AL047300; Créé le 13-MARS-1999 (Rel. 59) Dernière version le 20-FEVRIER-2000 (Rel. 62, Version 4) Caractérisation de la séquence : Homo sapiens mRNA; EST DKFZp586K1619_r1 (from clone DKFZp586K1619) *
LISCUM L, MUNN NJ.: "Intracellular cholesterol transport.", BIOCHIM BIOPHYS ACTA., vol. 1438, no. 1, 19 April 1999 (1999-04-19), pages 19 - 37, XP000889761 *
RUST, S. ET AL.: "Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy.", NATURE GENETICS., vol. 20, no. 1, September 1998 (1998-09-01), pages 96 - 98, XP000884511 *
SCHMITZ, G. ET AL.: "Tangier disease: defective recombination of a specific Tangier apolipoprotein A-I isoform (Proapo A-I) with high density lipoproteins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 80, no. 19, October 1983 (1983-10-01), NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US, pages 6081 - 6085, XP000877243, ISSN: 0027-8424 *
ZANNIS V I ET AL.: "ISOLATION AND SEQUENCE OF TANGIER APOLIPOPROTEIN A-I GENE.", ARTERIOSCLEROSIS, vol. 4, no. 5, 1984, pages 562A, XP000884780 *

Also Published As

Publication number Publication date
JP2003518918A (ja) 2003-06-17
EP1183350A2 (fr) 2002-03-06
KR20020033627A (ko) 2002-05-07
HUP0203164A2 (hu) 2002-12-28
WO2000071710A2 (fr) 2000-11-30
MXPA01011882A (es) 2002-05-06
AU4931800A (en) 2000-12-12
BR0010916A (pt) 2002-02-19
NO20015729D0 (no) 2001-11-23
IL145835A0 (en) 2002-07-25
NO20015729L (no) 2002-01-22
CA2371500A1 (fr) 2000-11-30

Similar Documents

Publication Publication Date Title
EP1005540A4 (fr) Proteines ikk-beta, acides nucleiques et procedes
WO2001072976A3 (fr) 32142, 21481, 25964, 21686, nouvelles molecules deshydrogenases humaines et utilisations
WO2003023000A3 (fr) Fragments d'adn lineaires destines a l'expression genetique
WO1998007850A3 (fr) Agents pour la detection pre-symptomatique et le ciblage therapeutique de la maladie d'alzheimer et du syndrome de down chez l'homme
CY1107552T1 (el) Ly6h γονιδιο
WO1997003192A3 (fr) Gene du chromosome 1 et produits genetiques lies a la maladie d'alzheimer
EP1657256A3 (fr) Compositions et méthodes pour traitement des tumeurs
CA2281895A1 (fr) Ikb kinases
WO2005079367A3 (fr) Synthase d'acide gras (fas) schizochytrium et produits et procedes connexes
WO2002040668A3 (fr) Proteines et sequences d'adn sous-jacentes a ces proteines, utilisees pour traiter les inflammations
CA2294566A1 (fr) Proteines ikk-.alpha., acides nucleiques et procedes
WO2000061742A3 (fr) Traitement d'une insuffisance cardiaque
WO2000019988A8 (fr) NOUVELLES MOLECULES SPECIFIQUES DE Th2 ET LEURS UTILISATIONS
WO2000071710A3 (fr) Produits d'expression de genes impliques dans des affections du metabolisme du cholesterol
WO2003062453A3 (fr) Acides nucleiques et proteines associes a la polykystose renale
WO2003029422A3 (fr) Gene du syndrome de noonan
WO2000040723A3 (fr) Methodes et produits servant a l'administration d'acides nucleiques
WO2002004513A3 (fr) Proteines 1 du type region critique 1 du syndrome de down
WO2002081650A3 (fr) Sequences nucleotidiques regulatrices d'alcool oxydase 1 pour l'expression de genes heterologues dans une levure
WO2003031594A3 (fr) Sequences de nucleotides et d'acides amines associees a des maladies respiratoires et a l'obesite
WO2001078894A3 (fr) Nouveau gene humain implique dans les maladies respiratoires, l'obesite et les maladies intestinales inflammatoires
WO2002064827A3 (fr) Acides nucleiques du gene humain abca12, vecteurs contenant ces acides nucleiques, et utilisations associees
WO2002006485A3 (fr) 47885, une nouvelle enzyme activant l'ubiquitine humaine et ses applications
WO2003051174A3 (fr) Polymorphismes de nucleotide unique (snp) et ses mutations dans l'alpha-2-macroglobuline
Oh et al. Promoter analysis of the Drosophila melanogaster gene encoding transcription elongation factor TFIIS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/01040/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2371500

Country of ref document: CA

Ref document number: 2371500

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/09129

Country of ref document: ZA

Ref document number: 200109129

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 515452

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 49318/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 620087

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011882

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017015017

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000931354

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09979715

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000931354

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017015017

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000931354

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017015017

Country of ref document: KR